ArticleNanotechnology, science and applications2026
The Potential of α-Mangostin-Loaded Chitosan/Collagen Nanoparticles in Hydrogel Formulation for Enhanced Wound Healing.
Article in Nanotechnology, science and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances and Future Perspectives on Chitosan-Sago-Derived Sodium Starch Glycolate as a Biopolymeric Carrier for Alpha-Mangostin Nanoparticles in Wound Healing.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic and acute wounds remain difficult to manage due to the inability of conventional dressings to provide sustained delivery of poorly soluble bioactives such as α-mangostin. This study investigates the potential of α-mangostin (AMG)-loaded chitosan/collagen nanoparticles (AMG-Ch/Coll NPs) incorporated into a hydrogel system for enhanced topical wound healing. Methods: Nanoparticles were prepared by ionic gelation and characterized for particle size, zeta potential, morphology (SEM), entrapment efficiency, and physicochemical interactions (FTIR, XRD, DSC). AMG solubility, including its apparent solubility in AMG-Ch NPs and AMG-Ch/Coll NPs was quantified. Subsequently, hydrogels incorporating AMG, AMG-Ch NPs, AMG-Ch/Coll NPs, and Ch-Coll NPs were formulated and evaluated for pH, spreadability, swelling ratio, and in vitro drug release. In vivo wound-healing efficacy was further assessed using a rat excision model. Results: Mean particle size increased from 297.10 ± 11.64 nm (AMG-Ch NPs) to 317.66 ± 8.76 nm (AMG-Ch/Coll NPs) and 339.62 ± 6.43 nm (Ch-Coll NPs), indicating the influence of collagen on particle size. FTIR, XRD, and DSC analyses confirmed the successful formation of amorphous nanoparticles with strong intermolecular interactions, contributing to enhanced structural stability and solubility. A fourfold improvement in AMG solubility was observed in the nanoparticle formulations, which were subsequently incorporated into hydrogel matrices and evaluated for topical application. All hydrogel (HG) formulations exhibited acceptable pH values (6.50-6.98) suitable for skin application. AMG-Ch NPs-HG demonstrated superior spreadability, swelling ratio, and drug release profiles, followed by AMG-Ch/Coll NPs-HG. Sustained AMG release was achieved, supporting prolonged bioavailability. In vivo wound healing studies in rats revealed that AMG-Ch NPs-HG and AMG-Ch/Coll NPs-HG significantly accelerated wound closure (99.28 ± 3.59% and 98.13 ± 3.26%, respectively, on day 21), outperforming AMG-HG (89.12 ± 2.58%), Ch/Coll NPs-HG (88.95 ± 3.14%), and the control group (79.84 ± 2.25%). Conclusion: Overall, these findings highlight the synergistic advantages of AMG-loaded Ch/Coll NPs in hydrogel formulations as a promising platform for enhanced topical wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.